Table I.
Correlation between clinicopathological features and the miR-155 expression level in GBCs.
| Clinicopathological features | Total | High expression | Low expression | P-value |
|---|---|---|---|---|
| Total no. of GBC cases | 26 | 13 | 13 | |
| Mean age, years ± SD (range) | 65±11 (42–85) | 66±11 (45–85) | 64±11 (42–83) | 0.66 |
| Gender, male/female (%) | 11 (42)/15 (58) | 8/5 | 6/7 | 0.67 |
| Presence of PBM (%) | 9 (35) | 3 | 6 | 0.97 |
| T category (UICC) (%) | ||||
| Tis/T1/T2 | 3 (12)/4 (15)/16 (61) | 0/1/11 | 3/3/5 | 0.56 |
| T3/T4 | 1 (4)/2 (8) | 0/2 | 1/0 | |
| N category, N1/N0 (%) | 5 (19)/21(81) | 5/8 | 0/13 | 0.03a |
| UICC stage (%) | ||||
| 0/IA/IB/IIA | 3 (12)/4 (15)/13 (50)/0 (0) | 0/1/8/0 | 3/3/5/0 | 0.11 |
| IIB/III/IV | 4 (15)/2 (8)/0 (0) | 3/2/0 | 1/0/0 | |
| Lymphatic invasion (%) | ||||
| Positive | 13 (50) | 9 | 4 | 0.11 |
| Negative | 13 (50) | 4 | 9 | |
| Vessel invasion (%) | ||||
| Positive | 13 (50) | 9 | 4 | 0.007a |
| Negative | 13 (50) | 3 | 10 | |
| Perineural invasion (%) | ||||
| Positive | 13 (50) | 5 | 8 | 0.11 |
| Negative | 13 (50) | 1 | 12 | |
| Follow-up period | ||||
| Median ± SD (months) | 35±33 | 25±19 | 46±40 | 0.29 |
| 5-year DSS rate | 0.62 | 0.46 | 0.83 | 0.01a |
miR, microRNA; GBC, gallbladder cancer; PBM, pancreaticobiliary maljunction; SD, standard deviation; DSS, disease-specific survival. Statistical significance was defined as a P-value of <0.05.
a
Indicates statistical significance.